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serendipity	 as	 “the	 faculty	 of	 making	 happy	 and	















example	 of	 chance	 discovery	 is	 penicillin.	 In	 1928,	
bacteriologist	Alexander	Fleming	discovered	 that	 the	





1982).	 However,	 they	 did	 not	 establish	 a	 biological	
connection	between	the	antibacterial	properties	of	mold	
and	 the	 treatment	 of	 diseases.	 In	 1940,	 Ernst	 Chain	
and	 Edward	 Penley	 Abraham	 developed	 a	 freeze-
drying	 protocol	 to	 concentrate	 penicillin.	 A	 further	
purification	 step	 based	 on	 absorption	 on	 activated	
charcoal	was	 further	provided	by	Christian	De	Duve	




Besides	 serendipity,	 a	 discovery	 also	 needs	
understanding	 of	 the	 mechanisms,	 transmission	 of	
knowledge	and	technical	development.	Today,	 thanks	
to	fortunate	happenstance,	several	bio-active	molecules	
have	 been	 isolated	 and	 are	 currently	 in	 clinical	 use.	
A	 recent	 review	estimated	 that	24%	of	 all	medicines	
available	 on	 the	 market	 (including	 antibiotics,	
psychotropic	drugs	and	anti-cancer	compounds)	were	
at	 least	 partly	 discovered	 serendipitously	 (Hargrave-
Thomas	 et	 al.,	 2012).	 In	 fact,	 this	 was	 the	 case	 for	





(e.g.	 epilepsy,	 schizophrenia,	 bipolar	 disorders).	
Due	 to	 its	 bioavailability	 and	 acceptable	 toxicity,	
2-propylpentanoic	 acid	 has	 also	 become	 one	 of	 the	




2. VALERIANA OFFICINALIS: THE ROOTS OF 
SUCCESS
The	 story	 began	 more	 than	 2,000	years	 ago	 with	 a	
flowering	plant	called	Valeriana officinalis,	also	known	
as	“All-heal”	(English),	“Baldrian”	(German),	“Herbe 
aux chats”	 (French).	The	dried	 rhizome	and	 roots	of	
V. officinalis	 are	 still	 used	 in	 traditional	medicine	 for	




to	 derive	 from	 the	 Latin	 word	 “valere”	 that	 means	
“healthy,	courageous,	strong,	powerful	or	brave”.	This	
Latin	word	 also	 refers	 to	 a	 famous	Roman	 Emperor	





Valerianaceae	 family,	V. officinalis	 is	 a	 tall	 perennial	






especially	 in	 Germany,	 The	Netherlands,	 Belgium	
and	 France	 (World	 Health	 Organization,	 1999).	 The	
cultivation	 and	 therapeutic	 uses	 of	 V. officinalis	 in	
Europe	 are	 approved	 by	 the	 European	 Medicines	
Agency.	The	 chemical	 composition	 of	 valerian	 roots	
depends	 on	 the	 growing	 conditions	 as	 well	 as	 the	
subspecies	 (ssp.	 officinalis,	 ssp.	 collina	 Nyman	 and	




sesquiterpenoid	 derivatives	 and	 alkaloids	 (Figure 1)	
(Upton,	1999;	Navarrete	et	al.,	2006;	Pharmacopoeia,	
2014).	 Over	 the	 centuries,	 traditional	 medicine	 used	
crude	 valerian	 extracts	 containing	 these	 molecules	
without	fully	understanding	the	mechanisms	involved,	
apparently	with	some	successful	therapeutic	responses.
The	 next	 step	 arose	 from	 the	 property	 of	 one	 of	
these	 compounds,	 valeric	 acid	 (or	 pentanoic	 acid),	 a	
short	chain	fatty	acid	and	its	derivatives.	Valeric	acid	
has	 an	 unpleasant	 odor	 like	 other	 short	 chain	 fatty	
acids	 from	 the	 gut	 such	 as	 butyric	 acid.	 In	 contrast,	
esters	of	valeric	 acid	 are	volatile	 and	widely	used	 in	
perfumes	 and	 cosmetics.	 Another	 key	 property	 of	
valeric	acid	results	from	its	structure,	which	combines	
a	 hydrophobic	 hydrocarbon	 chain	 with	 a	 carboxylic	
acid	 group	 (Figure 1).	 Due	 to	 the	 low	 hydrophobic	
nature	 of	 the	 alkyl	 chain,	 valeric	 acid	 is	miscible	 in	
water	and	can	be	used	to	solubilize	other	compounds.	
Analogs	of	valeric	acid	can	be	obtained	by	oxidation	
of	 primary	 alcohols	 and	 aldehydes	 with	 potassium	
permanganate	 or	 sodium	 chlorite.	 In	 1882,	 chemist	




alkaline	 decomposition	 of	 dipropylethyl	 acetoacetate	
A	biosourced	anticancer	agent	 3
with	 acetic	 acid,	 acetone	 and	 betaoxybutyric	 acid.	
Among	 other	 products	 such	 as	 dipropylacetone	 and	
dipropyl-β-oxybutyric	 acid,	 2-propylpentanoic	 acid	
had	 particularly	 interesting	 properties	 as	 an	 organic	
solvent	soluble	in	water.	
3. 2-PROPYLPENTANOIC ACID TO TREAT 
SEIZURE DISORDERS: A FORTUITOUS 
DISCOVERY 
In	1962,	Pierre	Eymard	and	colleagues	were	studying	
the	 anti-seizure	 activity	 of	 a	 series	 of	 khelline	
compounds	 in	 animal	models	 (Meunier	 et	 al.,	 1963).	
They	 faced	 a	major	 difficulty	 due	 to	 the	 insolubility	
of	 khelline	 in	 water	 as	 well	 as	 in	 other	 available	
solvents.	 Therefore,	 they	 used	 2-propylpentanoic	
Figure 1. Chemical	compounds	isolated	from	Valeriana officinalis roots — Composés chimiques isolés à partir des racines 
de Valeriana	officinalis.	
     Valerenic acid          Actinidine
     Valeric acid      Valepotriates
©		Julien	Piqueray
dipropylethyl acetoacetate  dipropylacetone
dipropyl-β-oxybutyric acid  2-propylpentanoic acid
Figure 2.	 Structure	 of	 compounds	 synthesized	 by	






acid	—	Instantané de l’article original publié en 1882 par 
Burton : On the propyl derivatives and decomposition of ethyl-
acetoacetate. American	Chemical	Journal, 3, 385-395. Burton 
synthétisa le dipropyléthyl acétoacétate, le dipropylacétone, 
l’acide dipropylbetaoxybutyrique et l’acide 2-propylpentanoïque.
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acid	 to	 dissolve	 methylene-cyano-norkhelline.	
Their	 experiment	 yielded	 promising	 results	 but	 also	
revealed	 that	 the	 control,	 2-propylpentanoic	 acid	
without	 khelline,	 had	 an	 anticonvulsant	 property	 by	
itself.	After	 evaluation	 of	 the	 therapeutic	 efficacy	 in	
human,	 2-propylpentanoic	 acid	 was	 validated	 as	 an	
anti-epileptic	 drug	 in	 France	 in	 1967	 and	 approved	
by	 the	 US	 Food	 and	 Drug	 Administration	 in	 1978	
with	 different	 trade	 names:	 Depakote,	 Depakene	
(Abbott	 Laboratories	 in	 US	 &	 Canada),	 Depakine	
and	 MicropakineLP	 (Sanofi-Aventis	 in	 Europe).	
2-propylpentanoic	 acid	 then	 became	 the	 main	
treatment	for	mood	disorders	(e.g.	epilepsy	and	bipolar	
depressive	syndrome).	In	addition,	2-propylpentanoic	
acid	 demonstrated	 efficacy	 towards	 agitation	 and	
aggressive	 behavior	 in	 patients	 presenting	 mental	
disorders.	Consistent	with	the	correlation	between	the	
anticonvulsant	action	and	reduced	neuronal	excitability,	
it	 was	 further	 demonstrated	 that	 2-propylpentanoic	
acid	 raises	 the	 brain	 levels	 of	 g-aminobutyric	 acid	
(GABA),	 a	 major	 inhibitor	 of	 neurotransmission	













2-propylpentanoic	 acid	 is	 efficiently	 transferred	 to	
the	peripheral	 blood	upon	oral	 administration.	 In	 the	
plasma,	 2-propylpentanoic	 acid	 can	 either	 be	 free	 or	
protein-bound	 (Kishore	et	al.,	2003).	With	a	half-life	
of	 approximately	 15-17	h,	 2-propylpentanoic	 acid	
undergoes	 hepatic	 catabolism	 through	 hydroxylation,	
glucuronidation	 and	 mitochondrial	 β-oxidation	
(Figure 3).	
Besides	 these	 remarkable	 properties,	
2-propylpentanoic	acid	unfortunately	increases	the	risk	
of	neural	 tube	defects	and	may	be	 teratogenic	during	
pregnancy	 (Nau	 et	 al.,	 1991).	 Other	 adverse	 effects	
mainly	include	moderate	hepatotoxicity	at	high	doses	
(Loscher,	2002).	
4. INHIBITION OF LYSINE ACETYLATION: 
A PROMISING TARGET FOR CANCER 
TREATMENT
The	 next	 milestone	 issued	 from	 studies	 focusing	 on	
the	molecular	mechanisms	of	2-propylpentanoic	acid	
associated	 teratogenicity.	A	key	observation	was	 that	
2-propylpentanoic	 acid	 stimulates	 the	 peroxisome-
activated	 receptor-δ	 (PPAR-δ)	 at	 the	 transcriptional	
level	 without	 interfering	 with	 its	 ligand	 binding	 site	
(Gottlicher	 et	 al.,	 2001).	 PPARs	 are	 ligand-inducible	
nuclear	 receptors	 involved	 in	 lipid	 metabolism	 and	
glucose	 homeostasis.	 In	 the	 early	 2000s,	 PPAR-δ	
expression	 was	 associated	 with	 inhibition	 of	 histone	
deacetylase	 (HDAC)	 activity	 by	 2-propylpentanoic	
acid.	By	neutralizing	or	exposing	the	positively-charged	
lysine	residues	of	N-terminal	of	histone	tails,	histone	
acetyltransferases	 (HAT)	 and	 HDACs	 finely	 tune	
chromatin	condensation	(Figure 3).	2-propylpentanoic	
acid	is	a	broad	spectrum	inhibitor	affecting	both	class	I	




The	 availability	 of	 a	 pharmacological	 tool	
affecting	 gene	 expression	 opened	 new	 insights	
into	 the	 understanding	 of	 the	 epigenetic	 control	 of	
gene	 expression	 and	 DNA	 replication.	 Even	 more	
importantly,	 well-tolerated	 HDAC	 inhibitors	 such	
as	 2-propylpentanoic	 acid	 also	 became	 therapeutic	
drugs	for	the	treatment	of	cancer.	Indeed,	cancer	cells	
are	 characterized	 by	 genetic	 alterations	 but	 also	 by	
inadequate	expression	of	tumor	suppressor	genes.	The	
model	was	successfully	challenged	in	an	animal	model	
of	 leukemia	 and	 then	 further	 validated	 in	 humans	
(Achachi	et	al.,	2005;	Lezin	et	al.,	2007;	Vandermeers	
et	al.,	2009;	Hubaux	et	al.,	2010).	Although	the	modes	
of	 action	 of	 2-propylpentanoic	 acid	 still	 require	
clarification,	the	treatment	appeared	to	be	remarkably	
well	 tolerated.	 The	 anticancer	 mechanisms	 include	
activation	 of	 gene	 transcription,	 cell	 cycle	 arrest,	
modulation	 of	 intracellular	 signaling	 and	 of	 reactive	







or	 the	 peritoneum,	 which	 is	 induced	 by	 exposure	 to	
asbestos	 fibers.	 Among	 45	MM	 relapsing	 patients	
treated	with	 a	 combination	of	 2-propylpentanoic	 and	
doxorubicin	 (a	 DNA	 topoisomerase	 inhibitor),	 there	
were	 16%	 partial	 responses	 and	 9%	 stable	 diseases.	
Although	 still	 modest,	 these	 scores	 are	 nevertheless	
quite	encouraging	considering	the	lack	of	response	in	
MM	relapsing	patients	treated	with	doxorubicin	alone.	
Although	 progression	 free	 survival	 is	 not	 prolonged,	
the	new	regimen	has	the	remarkable	ability	to	relieve	






















decondensates	chromatin	and	favors	gene	expression	—	L’acide 2-propylpentanoïque est métabolisé par les cellules du foie via 
trois voies métaboliques : la glucuronidation par l’UDP-glucuronyl transférase (UPGT), l’hydroxylation par le cytochrome P450 
(CYP450) et l’oxydation mitochondriale via l’acétyl-CoA déshydrogénase. L’acide 2-propylpentanoïque augmente la concentration 
de l’acide γ-aminobutyrique (GABA) dans le cerveau en inhibant la semi-aldéhyde déhydrogénase succinique (SSADH). L’acide 
2-propylpentanoïque inhibe les désacétylases d’histone (HDAC) et augmente l’acétylation des résidus lysines des queues aminoterminales 
des histones. L’acétylation des groupements amines des lysines par l’histone acétyltransférase (HAT) réduit leur affinité pour l’ADN, 
décondense la chromatine et favorise l’expression génique.
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still	 preserving	 optimal	 tolerability.	 This	 perspective	
will	be	a	major	issue	of	the	AgricultureIsLife	program.	
5. CONCLUSIONS 
In	 this	 review,	 we	 have	 described	 the	 story	 of	 a	
compound,	2-propylpentanoic	acid,	starting	from	crude	
extracts	 of	 Valeriana officinalis	 used	 in	 traditional	
medicine	and	progressing	 to	 the	demonstration	of	 its	
ability	to	improve	cancer	treatment.	This	story	reveals	
that	 the	 development	 of	 a	 useful	 bio-sourced	 drug	
requires	 the	 achievement	 of	 a	 series	 of	 milestones;	
include	 both	 an	 understanding	 of	 the	 biological	
mechanisms	 as	 well	 as	 technical	 developments	
where	 bottlenecks	 were	 bypassed	 thanks	 to	 chance,	
perspicacity	and	scientific	curiosity.	
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Table 1.	Ongoing	clinical	trials	of	2-propylpentanoic	acid	in	cancer	therapy	—	Essais cliniques évaluant l’effet de l’acide 
2-propylpentanoïque dans le traitement du cancer.
Combination with 
2-propylpentanoic acid
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